ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Leede Jones Gable starts ProMIS at speculative buy; PT 50

<< Previous

Bullboard Posts

Next >>

Comment by retiredcopon May 16, 2022 4:14pm

135 Views

Post# 34687323

RE:RE:RE:Leede Jones Gable starts ProMIS at speculative buy; PT 50

LJG has one very important short-term goal ..they have made it public that they anticipate the stock moving to 50 cents Can.... I say they will have a lot of input in achieving that prediction otherwise no other reason to make that claim and that's about the perfect time to make the Nasdaq move... invisible forces working in the background now that annual general meeting and board securely in place

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario